alum
adjuv
approv
clinic
applic
induc
strong
humor
weak
cellular
immun
respons
necessari
develop
safe
effect
adjuv
capabl
induc
humor
cellular
immun
respons
previous
show
activationassoci
deriv
onchocerca
volvulu
potent
adjuv
activ
studi
evalu
adjuvant
recombin
use
panel
recombin
protein
synthet
peptidebas
antigen
includ
ovalbumin
ova
synthet
hiv
peptid
hivp
recombin
hiv
hbv
hbsag
well
three
commerci
avail
inactiv
vaccin
haemorrhag
fever
renal
syndrom
hfr
influenza
rabi
result
indic
induc
significantli
higher
respons
alum
adjuv
ova
antigen
hivp
consist
induc
similar
level
respons
alum
higher
level
cell
respons
alum
adjuv
hbsag
improv
respons
three
commerci
inactiv
vaccin
use
separ
combin
conclus
recombin
unlik
alum
adjuv
abl
induc
humor
respons
cellular
respons
suggest
develop
promis
adjuv
subunitbas
inactiv
vaccin
success
immun
character
induct
appropri
immun
respons
includ
humor
cellular
immun
respons
thelper
base
immun
respons
essenti
control
intracellular
infect
immun
respons
use
control
extracellular
infect
sinc
adjuv
help
induc
effect
appropri
immun
respons
variou
antigen
use
import
compon
vaccin
although
vaccin
adjuv
use
almost
centuri
alum
adjuv
current
licens
us
fda
clinic
use
increas
immun
respons
proteinbas
vaccin
unfortun
alum
abl
induc
strong
antibodi
respons
poor
stimul
cellular
immun
respons
import
protect
mani
pathogen
addit
alum
may
caus
seriou
sever
local
system
side
effect
granuloma
allergen
neurotox
steril
abscess
myofasc
thu
limit
alum
restrict
use
vaccin
adjuv
recombin
antigen
consequ
critic
need
safer
effect
adjuv
suitabl
human
use
particularli
abl
stimul
cellular
immun
sever
agent
test
potenti
adjuv
induc
immun
respons
vaccin
antigen
report
unmethyl
cpg
oligodeoxynucleotid
odn
may
induc
domin
respons
aspergillu
antigen
allergen
fungu
well
improv
effici
alumbas
adjuv
vaccin
anim
adjuv
formul
polylactidecoglycolid
plg
may
maintain
improv
immun
efficaci
vaccin
antigen
includ
men
c
tetanu
toxoid
tt
hbsag
may
serv
altern
alum
use
activ
associ
secret
protein
asp
belong
nematodespecif
protein
famili
potenti
vaccin
compon
previous
investig
sever
research
group
recent
recombin
secret
protein
helminth
onchocerca
volvulu
identifi
group
exhibit
potent
augment
effect
immun
respons
adjuv
efficaci
exceed
alum
monophosphoryllipid
mpl
trehalos
dicorynomycol
tdm
adjuv
investig
adjuv
effect
recombin
immun
respons
induc
seri
protein
peptid
antigen
commerci
avail
inactiv
vaccin
three
major
infecti
diseas
encod
amino
acid
protein
amplifi
polymeras
chain
reaction
pcr
base
codonoptim
gene
insert
express
vector
invitrogen
carlsbad
ca
protein
express
six
histidinetag
e
coli
form
inclus
bodi
cell
pellet
contain
insolubl
protein
solubil
urea
overnight
follow
purif
ureasolubl
protein
nichromatographi
novagen
gibbstown
nj
elut
fraction
histidin
column
analyz
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
western
blot
brief
purifi
protein
separ
sdspage
transfer
nitrocellulos
membran
amersham
bioscienc
piscataway
nj
blot
block
overnight
skim
milk
pb
contain
tween
pbst
follow
incub
mous
antihi
antibodi
h
room
temperatur
blot
wash
three
time
incub
hrpconjug
antimous
igg
zyme
san
francisco
ca
h
room
temperatur
signal
visual
ecl
western
blot
substrat
reagent
amersham
bioscienc
kodak
biomax
scientif
imag
film
perkinelm
boston
express
protein
also
confirm
polyclon
antibodi
produc
lab
ovalbumin
ova
sigma
st
loui
mo
hiv
peptid
hivp
deriv
caveolin
bind
domain
aa
sleviwnnmtwmewereidn
first
use
model
antigen
test
adjuvant
protein
ova
select
usual
induc
immun
respons
without
help
adjuv
recombin
express
baculoviru
system
perf
scientif
beij
china
recombin
hepat
b
surfac
antigen
hbsag
express
pichiayeast
express
system
kangtai
biotechnolog
shenzhen
china
also
use
test
addit
test
effect
protein
immun
respons
three
commerci
avail
inactiv
viru
vaccin
epidem
infecti
diseas
includ
haemorrhag
fever
renal
syndrom
hfr
inactiv
vaccin
zhejiang
tianyuan
biopharmaceut
co
ltd
china
influenza
inactiv
split
vaccin
vaxigrip
manufactur
sanofi
pasteur
sa
fill
packag
shenzhen
sanofi
pasteur
biolog
product
co
ltd
china
rabi
inactiv
vaccin
verorab
manufactur
sanofi
pasteur
sa
fill
packag
shenzhen
sanofi
pasteur
biolog
product
co
ltd
fiveweekold
male
balbc
mice
respect
immun
protein
peptid
antigen
commerci
inactiv
viru
vaccin
group
protein
peptid
antigen
mice
subcutan
sc
vaccin
ova
hivp
hbsag
respect
mix
ml
pb
alum
sigma
pb
adjuv
control
group
commerci
avail
inactiv
vaccin
mice
intramuscularli
im
vaccin
vaccin
separ
combin
combin
contain
individu
vaccin
presenc
absenc
mice
boost
week
postimmun
ova
inactiv
vaccin
group
boost
twice
interv
group
mous
preimmun
sera
antisera
collect
prevaccin
postboost
vaccin
respect
store
detect
antibodi
respons
igg
isotyp
antigen
measur
elisa
briefli
ova
hivp
hbsag
antigen
respect
coat
elisa
plate
concentr
ova
hivp
hbsag
carbon
buffer
ph
overnight
inactiv
viru
vaccin
antigen
coat
dilut
hfr
rabi
concentr
influenza
five
wash
plate
block
bsa
h
mous
sera
serial
dilut
pb
ad
well
follow
incub
plate
h
extens
wash
enzymelink
goat
antimous
antibodi
bethyl
compani
montgomeri
tx
ad
dilut
h
substrat
tmb
zyme
ad
plate
reaction
stop
ad
h
absorb
nm
measur
multiskan
elisa
reader
thermo
labsystem
franklin
assay
perform
use
elispot
mous
kit
bd
bioscienc
beij
china
accord
manufactur
protocol
brief
elispot
plate
coat
antimous
mab
overnight
block
steril
rpmi
contain
fb
h
room
temperatur
singlecel
suspens
prepar
spleen
hbsagvaccin
mice
ad
well
concentr
cellswel
cell
incub
h
presenc
absenc
epitopespecif
stimulu
hbsp
wywgpslysi
co
atmospher
plate
wash
pb
follow
incub
biotinylatedlabel
antimous
mab
h
room
temperatur
addit
wash
well
incub
streptavidinconjug
hrp
h
room
temperatur
plate
extens
wash
develop
tmb
substrat
solut
includ
kit
spot
cell
count
use
autom
elispot
reader
system
immunospot
softwar
cellular
technolog
beij
china
result
express
number
spotform
cell
sfc
per
input
cell
valu
present
mean
standard
error
se
statist
signific
among
differ
vaccin
group
calcul
student
ttest
use
stata
statist
softwar
valu
p
consid
signific
recombin
express
purifi
e
coli
character
sdspage
western
blot
data
shown
protein
ova
initi
use
model
antigen
evalu
adjuvant
ova
use
alon
togeth
alum
respect
vaccin
mice
mous
sera
collect
test
respons
shown
fig
b
ova
alon
induc
neither
respons
without
adjuv
presenc
alum
ova
abl
elicit
weak
respons
respons
contrast
could
dramat
augment
respons
ova
wherea
alon
induc
detect
immun
respons
result
indic
possess
high
adjuv
effect
induct
respons
ova
vaccin
anim
analysi
time
point
induc
igg
isotyp
demonstr
titer
ova
group
exhibit
similar
trend
titer
ova
alum
group
ie
increas
rapidli
week
postvaccin
reach
peak
week
postprim
vaccin
maintain
high
level
least
week
postprim
vaccin
respons
ova
group
also
show
similar
trend
higher
antibodi
titer
wherea
titer
ova
alum
group
almost
undetect
time
point
fig
ratio
ova
antigen
plu
alum
significantli
higher
use
adjuv
tabl
suggest
abl
potenti
antibodi
respons
protein
antigen
distinct
bia
antibodi
respons
consist
previou
report
confirm
enhanc
immun
respons
protein
ova
antigen
test
whether
protein
adjuv
stimulatori
effect
synthet
peptid
human
pathogen
peptid
hiv
hivp
use
experi
balbc
mice
immun
combin
plu
hivp
compar
result
hivp
without
commerci
adjuv
alum
induct
isotyp
detect
hivp
mous
sera
ratio
calcul
tabl
fig
show
titer
hivp
group
significantli
higher
three
group
boost
vaccin
p
higher
titer
reach
week
boost
vaccin
hivp
fig
significantli
increas
boost
vaccin
fig
comparison
significantli
lower
level
especi
induc
hivp
hivp
alum
group
fig
b
shown
better
adjuv
alum
stimul
product
antibodi
commerci
ova
antigen
synthet
hivp
peptid
test
whether
similar
adjuv
potenc
recombin
protein
deriv
human
pathogen
accomplish
mice
vaccin
mix
recombin
baculovirusexpress
hiv
protein
result
compar
commerci
alum
adjuv
gener
result
shown
fig
indic
combin
induc
higher
level
induc
alum
p
specif
titer
increas
rapidli
boost
vaccin
titer
repres
signific
increas
alum
detect
either
p
fig
appear
boost
vaccin
could
increas
titer
similarli
titer
group
significantli
higher
alum
group
boost
vaccin
p
fig
unlik
alum
group
group
maintain
low
level
ratio
confirm
abl
potenti
respons
respect
tabl
result
indic
repres
substanti
improv
alum
stimul
igg
isotyp
respons
recombin
protein
particular
abil
induc
strong
antibodi
respons
yeastexpress
recombin
hbsag
protein
use
next
experi
confirm
adjuvant
recombin
antigen
fig
b
show
although
titer
slightli
lower
group
alum
group
boost
vaccin
differ
statist
signific
p
contrast
titer
induc
hbsag
significantli
higher
induc
hbsag
alum
boost
vaccin
p
result
suggest
adjuvant
hbsag
protein
might
bias
toward
respons
also
indic
low
level
antihbsag
ratio
tabl
confirm
adjuvant
induc
respons
splenocyt
hbsagvaccin
mice
collect
h
poststimul
hbsagspecif
cell
epitop
hbsp
detect
cell
elispot
shown
fig
hbsag
induc
cell
significantli
higher
induc
hbsag
alum
p
thu
potenti
adjuv
abl
induc
hbsagspecif
cell
immun
respons
recombin
hbsagvaccin
mice
coincid
induct
antibodi
result
demonstr
may
stimul
level
respons
similar
alum
adjuv
even
higher
level
cell
respons
hbsag
protein
suggest
strong
adjuvnat
confirm
adjuvant
induct
igg
isotyp
respons
protein
peptidebas
antigen
want
determin
could
similarli
improv
immun
effect
commerci
avail
inactiv
vaccin
hfr
vaccin
vaccin
influenza
vaccin
vaccin
b
rabi
vaccin
vaccin
c
use
test
isotyp
respons
detect
mous
sera
respect
vaccin
vaccin
separ
combin
three
vaccin
reduc
dose
individu
vaccin
presenc
absenc
first
fig
show
may
significantli
improv
induct
singl
inactiv
vaccin
exampl
vaccin
stimul
induc
significantli
higher
level
antibodi
vaccin
vaccin
alon
p
fig
similarli
induct
vaccin
c
antibodi
also
significantli
higher
vaccin
c
vaccin
c
without
p
fig
case
induct
signific
differ
obtain
vaccin
b
vaccin
b
without
p
fig
vaccin
c
vaccin
c
without
p
fig
respons
induc
significantli
higher
induc
abc
without
fig
similar
result
obtain
antib
c
antibodi
respons
induc
abc
vaccin
presenc
absenc
test
fig
c
result
suggest
may
use
potenti
adjuv
improv
immun
respons
commerci
vaccin
vaccin
administr
separ
combin
result
also
suggest
may
help
balanc
immun
respons
combin
vaccin
use
togeth
reduct
dosag
decreas
potenti
side
effect
otherwis
produc
induct
multipl
vaccin
without
affect
vaccin
efficaci
vaccin
import
compon
antivir
immun
respons
higher
safeti
profil
less
toxic
inject
site
result
pure
recombin
synthet
antigenbas
vaccin
becom
current
trend
vaccin
develop
howev
subunitbas
vaccin
adjuv
stimul
usual
less
immunogen
tradit
live
wholekil
organismbas
vaccin
major
advantag
creat
high
demand
power
adjuv
use
subunit
vaccin
although
vaccin
adjuv
bo
report
induc
mix
antibodi
cellular
immun
respons
pathogen
antigen
mani
adjuv
studi
date
less
effect
caus
inflammatori
respons
alum
adjuv
approv
human
use
worldwid
mainli
associ
respons
littl
capac
stimul
cellular
immun
respons
therefor
urgent
develop
adjuv
effect
induc
humor
immun
respons
also
cellular
immun
respons
member
protein
famili
found
freeliv
parasit
nematod
nativ
protein
natur
occur
secret
helminth
live
year
human
host
initi
studi
indic
vaccin
mice
recombin
may
stimul
high
titer
significantli
exceed
efficaci
alum
mpl
tdm
adjuv
indic
strike
potenti
protein
novel
adjuv
human
use
studi
comprehens
research
carri
protein
evalu
adjuvant
start
point
ova
antigen
synthet
peptid
hiv
hivp
use
test
adjuvant
recombin
ova
protein
wide
use
model
antigen
adjuvant
detect
sinc
protein
abil
induc
immun
respons
without
adjuv
turn
effect
elicit
antibodi
cellular
respons
mice
immun
unrel
ova
protein
hiv
synthet
peptid
adjuvant
exceed
alum
adjuv
especi
induct
isotyp
fig
tabl
two
recombin
protein
hbsag
use
elucid
adjuvant
subunitbas
vaccin
two
protein
select
import
pathogen
antigen
two
major
infecti
diseas
hiv
hepat
b
result
hiv
mice
confirm
abil
stimul
respons
recombin
hiv
protein
effect
commerci
alum
adjuv
fig
even
though
alum
weak
abil
induc
cellular
respons
often
use
adjuv
combin
hbsag
surfac
antigen
hbv
infect
therefor
use
stimulu
hbsag
test
adjuvant
compar
alum
abil
induc
respons
hbsag
equival
alum
howev
result
indic
abil
induc
respons
still
outperform
alum
demonstr
product
similar
level
higher
level
cell
respons
fig
result
therefor
confirm
advantag
tradit
alum
adjuv
formul
hbv
vaccin
final
base
three
commerci
vaccin
hfr
influenza
rabi
studi
also
aim
determin
whether
could
improv
immun
efficaci
current
inactiv
vaccin
accomplish
vaccin
either
use
independ
combin
dosag
singl
vaccin
plu
importantli
could
increas
addit
either
singl
vaccin
group
combin
group
fig
equal
higher
immun
respons
detect
three
vaccin
combin
suggest
may
help
vaccin
combin
induc
effect
singl
vaccin
less
dosag
indic
potenti
induc
side
effect
combin
vaccin
could
elimin
result
demonstr
potenti
adjuv
abil
improv
efficaci
commerci
inactiv
vaccin
conclus
studi
demonstr
recombin
induc
higher
level
immun
respons
commerci
produc
alum
adjuv
unlik
alum
protein
adjuv
abil
stimul
mix
strong
immun
respons
result
also
indic
potenti
adjuvant
induc
immun
respons
recombin
subunitbas
vaccin
synthet
peptid
well
improv
immun
efficaci
commerci
inactiv
vaccin
suggest
potenc
promis
develop
practic
adjuv
human
use
evalu
adjuvant
synthet
hivp
peptid
group
mice
respect
vaccin
hivp
hivp
mous
sera
collect
week
boost
detect
elisa
igg
isotyp
concentr
alum
use
control
induct
b
postboost
vaccin
compar
respect
hivp
hivp
alum
hivp
vaccin
group
data
present
geometr
mean
titer
se
five
mous
sera
group
p
compar
hivp
hivp
alum
group
evalu
hbsag
epitopespecif
respons
elispot
splenocyt
six
vaccin
mice
stimul
hbsagspecif
cell
peptid
hbsp
h
cultur
medium
without
stimulu
appli
neg
control
nc
frequenc
cell
express
mean
valu
spotform
cell
sfc
per
splenocyt
five
independ
experi
p
compar
hbsag
alum
group
evalu
igg
isotyp
respons
commerci
vaccin
group
six
mice
respect
vaccin
singl
commerci
vaccin
three
vaccin
combin
presenc
absenc
mous
sera
collect
week
postboost
vaccin
induc
respect
vaccin
antigen
detect
elisa
induct
vaccin
p
compar
abc
without
antia
respect
b
induct
vaccin
b
p
compar
b
b
abc
without
antib
respect
c
induct
vaccin
c
p
compar
c
c
abc
without
antic
respect
data
present
geometr
mean
titer
se
six
mous
sera
group
vaccin
hfr
vaccin
vaccin
b
influenza
vaccin
vaccin
c
rabi
vaccin
inactiv
vaccin
three
major
infecti
diseas
hfr
influenza
rabi
